May 13, 2016 12:09pm

ADRO’s first patient dosed in P1 study of ADU-S100 to treat cutaneous accessible tumors; partner Novartis is conducting the study.



The first patient has been dosed in a P1 trial for ADU-S100 (also known as MIW815), a novel STING (Stimulator of Interferon Genes) pathway activator.


Activation of the STING pathway in tumors has been shown to be a critical step to initiate an innate response that may lead to a systemic adaptive tumor-specific immune response.

Novartis, Aduro’s collaborator for STING pathway activator compounds in the field of oncology, is conducting the study.

The P1, multicenter, dose escalation study, includes dose expansion into designated indications, will enroll patients with cutaneous accessible metastatic solid tumors or lymphomas who are in need of other treatment alternatives.

The trial is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of ADU-S100 (MIW815). For more information about the clinical trial, please visit and use identifier NCT02675439.


The Bottom Line: ADRO eligible for up to $465 M more in development and regulatory milestones under R&D alliance pact with Novartis signed last year in March 2015

ADRO had $408.5m cash, equivalents and marketable securities as of March 31

ADRO is up +$0.65 or +6.37% to $10.86 on low volume <3 month average = 42.7 K shares>